Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
08/05/2022 - 08:00 AM
BRIDGEWATER, N.J. Aug. 5, 2022
In connection with the commencement of their employment, the employees received options on August 1, 2022 to purchase an aggregate 53,570 shares of Insmed common stock at an exercise price of $20.88 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.
The options have a 10-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the relevant grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary of the relevant grant date, subject to the relevant employee's continued service with Insmed on the applicable vesting date.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States , Europe , and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey , with a footprint across Europe and in Japan . For more information, visit www.insmed.com .
Contact:
Investors:
Eleanor Barissereleanor.barisser@insmed.com
Media:
Mandy Fahey amanda.fahey@insmed.com
https://www.prnewswire.com/news-releases/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301598045.html
SOURCE Insmed Incorporated
INSM Rankings
#546 Ranked by Stock Gains
INSM Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Bridgewater
About INSM
insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. the company is dedicated to developing and bringing to market therapies that make a real difference in patients’ lives, while striving to understand and enhance the entire patient experience, from diagnosis and treatment to everyday living. headquartered in bridgewater, nj, we are a rapidly growing company with offices in seven countries.
